Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benzodiazepine hypnotics and insomnia.

A Kales1

  • 1Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey.

Hospital Practice (Office Ed.)
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reassessment of triazolam.

The International journal of risk & safety in medicine·2013
Same author

Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression.

The Journal of clinical endocrinology and metabolism·2005
Same author

Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines.

The Journal of clinical endocrinology and metabolism·2004
Same author

Insomnia in central Pennsylvania.

Journal of psychosomatic research·2002
Same author

Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime.

Metabolism: clinical and experimental·2002
Same author

Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.

The Journal of clinical endocrinology and metabolism·2001
Same journal

Oral contraceptives: an update.

Hospital practice (Office ed.)·1995
Same journal

Progress in the immunogenetics of rheumatoid arthritis.

Hospital practice (Office ed.)·1995
Same journal

An asymptomatic lung nodule in an elderly woman with joint pain.

Hospital practice (Office ed.)·1995
Same journal

Defusing status epilepticus.

Hospital practice (Office ed.)·1995
Same journal

Persistent fever and flank discomfort in a young woman.

Hospital practice (Office ed.)·1995
Same journal

New thoughts on attention-deficit/hyperactivity disorder.

Hospital practice (Office ed.)·1995
See all related articles

Triazolam

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medicinal Chemistry

Background:

  • Triazolam, a triazolo-benzodiazepine, exhibits a unique side effect profile compared to other benzodiazepines.
  • Factors influencing triazolam's adverse reactions include rapid elimination, high receptor-binding affinity, and unique chemical properties.

Purpose of the Study:

  • To explain the side effect profile of triazolam.
  • To compare the safety and efficacy of triazolam with other benzodiazepines like flurazepam and temazepam.

Main Methods:

  • Comparative analysis of pharmacokinetic and pharmacodynamic properties of benzodiazepines.
  • Evaluation of reported central nervous system (CNS) adverse reactions and their correlation with drug characteristics.

Main Results:

Related Experiment Videos

  • Triazolam's rapid elimination and high receptor affinity contribute to hyperexcitability states and cognitive impairments.
  • Slower-elimination benzodiazepines like flurazepam show fewer adverse CNS reactions.
  • Temazepam has a favorable safety profile but limited efficacy for sleep induction compared to flurazepam.

Conclusions:

  • Triazolam's safety profile, characterized by frequent and severe adverse reactions, combined with limited efficacy at 0.25 mg, raises concerns about its benefit-risk ratio.
  • The 0.25 mg dose of triazolam may have a poor benefit-risk ratio, questioning its continued market availability.